Torres HA et al. -Direct-acting antivirals (DAAs) have changed HCV treatment strategies, but the optimal management of HCV infection in patients with cancer has not been established. Based on the current review, it is recommended that HCV-infected patients with cancer who have cirrhosis or advanced fibrosis, and those at risk for liver disease progression, especially patients with HCV-associated comorbidities, should have ongoing follow-up. HCV-infected patients with a sustained virologic response should also be monitored closely to ensure timely detection and treatment of hepatocellular carcinoma. HCV infection and its treatment should not be considered contraindications to cancer treatment and should not delay the initiation of cancer therapy.